Remestemcel-L - Mesoblast

Drug Profile

Remestemcel-L - Mesoblast

Alternative Names: hMSC - Mesoblast; human mesenchymal stem cells - Mesoblast; JR-0301; JR-031; MSC-100; MSC-100-IV; OTI-010; OTI-020; OTI-021; Prochymal; Provacel; Stromagen; TEMCELL HS Inj.

Latest Information Update: 09 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Osiris Therapeutics
  • Developer JCR Pharmaceuticals; Mesoblast; Osiris Therapeutics
  • Class Antineoplastics; Ischaemic heart disorder therapies; Stem cell therapies
  • Mechanism of Action Cell replacements; Tissue replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease; Type 1 diabetes mellitus
  • New Molecular Entity No

Highest Development Phases

  • Marketed Graft-versus-host disease
  • Phase III Crohn's disease
  • Phase II Myocardial infarction
  • Discontinued Acute radiation syndrome; Chronic obstructive pulmonary disease; Type 1 diabetes mellitus

Most Recent Events

  • 20 Sep 2018 Mesoblast announces intention to submit BLA to the US FDA for Graft-versus-host disease
  • 20 Sep 2018 Mesoblast plans to launch remestemcel-L for Graft-versus-host disease in the US
  • 20 Sep 2018 Updated efficacy data from a phase III trial in Graft-versus-host disease released by Mesoblast
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top